Abstract 477P
Background
Lower grade gliomas (LGGs) represent 15% of all primary brain tumors, and have variable prognosis. The prognostic influence of the ENHO gene in LGGs remains elusive, necessitating further bioinformatic exploration to improve patient management and outcomes.
Methods
Differential gene expression based on High/low ENHO expression was extracted using the “DESeq2” R package. Immune infiltration, mutational burden, gene set variation analysis (GSVA) and drug resistance were analyzed through GSCALite and cBioPortal. Additional immune infiltration and survival analysis used TIMER2.0. Gene set enrichment analysis (GSEA) was conducted via TCGAbiolinks and enriched further using Enrichr.
Results
Multivariate overall survival (OS) analysis showed a protective effect for ENHO (HR = 0.58, p <0.001). GSVA for OS and progression-free survival (PFS) for co-expressed genes and upregulated genes also showcased favorable prognosis OS:(HR = 0.40, p<0.001) and (HR = 0.34, p<0.001), respectively; PFS: (HR = 0.53, p<0.001) and (HR = 0.44, p<0.001), respectively. Survival GSVA of downregulated genes revealed an association with worse OS (HR = 4.19, p < 0.001) and PFS (HR = 2.45, p< 0.001). GSVA for upregulated genes showed a negative correlation with DNA damage, EMT, and PI3KAKT pathways. GSVA for downregulated genes had a positive correlation with EMT, DNA damage, and PI3K/AKT pathways. GSVA for co-expressed genes revealed significant negative correlations with DNA damage and EMT pathways. Mutational burden analysis revealed that shallow deletion is the most common ENHO mutation among all LGG subtypes, regardless of stage. Immune infiltration analysis for ENHO, upregulated, and co-expressed genes showcased the infiltration of: Central memory B cells, CD8 T cells, Neutrophils, and CD4 T cells. Decreased infiltration of cancer associated fibroblasts was observed for high ENHO expression. GSEA of coexpressed genes revealed significant involvement in cell cycle processes and regulation.
Conclusions
ENHO's role in LGG is yet to be determined, but our results showcase a possible protective effect through its modulation of the immune system, cell cycle signalling, and EMT pathways. Primary studies are still needed to validate ENHO's role in LGG.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
566P - Impact of weekly irinotecan’s cycles during preoperative chemoradiotherpy in locally advanced rectal cancer: A post-hoc analysis of the CinClare study
Presenter: Ji Zhu
Session: Poster session 16
567P - Interim endoscopic restaging after induction chemotherapy to predict complete response and survival after total neoadjuvant therapy in low rectal cancer: Ad-hoc analysis of the IMPACT trial
Presenter: Eiji Shinozaki
Session: Poster session 16
568P - Risk factors for recurrence after surgery for rectal cancer in a modern, nationwide population-based cohort
Presenter: Sepehr Doroudian
Session: Poster session 16
569P - Mismatch repair deficient, stage II/III rectal cancer: Real-world patient, tumour, and treatment characteristics in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
571P - Neoadjuvant chemotherapy with FOLFIRINOX and short course radiotherapy in locally advanced rectal caner (ISANOX): A prospective phase II trial
Presenter: Feryel Letaief-Ksontini
Session: Poster session 16
572P - Tolerance of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34 – FFCD 1402 - ADAGE randomized phase III trial
Presenter: Thomas Aparicio
Session: Poster session 16
573P - M9140, an anti-CEACAM5 antibody drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): Updated results from a phase I trial
Presenter: Valentina Boni
Session: Poster session 16
574P - First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study
Presenter: Zhen Yu Lin
Session: Poster session 16
575P - Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results
Presenter: Andrew Hendifar
Session: Poster session 16